# Supplemental Data

**Supplementary Figure 1. PK of (A) abemaciclib (150 mg PO Q12H), (B) pembrolizumab (200mg iv Q21D), and (C) anastrozole (1 mg PO Q24H)**



**Figure Legend**: Arithmetic mean plasma concentration over time for (A) abemaciclib (ng/mL), (B) pembrolizumab (µg/mL) and (C) anastrozole (ng/mL). Error bars indicate standard deviation.

**Abbreviation:** IV = intravenous administration; PO = oral administration; Q21H = every 12 hours; Q21D = every 21 days; Q24H = every 24 hours

**Supplementary Figure 2. Best percent change in tumor size from baseline (RECIST version 1.1) according to PD-L1 status in Cohort 2[a]**




**Figure legend:** Best percent change in tumor size from baseline is presented for the safety population in cohort 1. The PD-L1 protein expression was assessed by an IHC assay in tumor tissue samples (see Methods).

[a]Due to sample size limitation (Table 1), the anticancer activity by PD-L1 status was not presented for cohort 1

**Note:** Patients without any post baseline data are not included in the graphs.

**Abbreviation:** CR, complete response; CI, confidence interval; NE, non-estimable; ORR, overall response rate; OS, overall survival; PFS, progression free survival; PD-L1, Programmed death-ligand 1; PR, Partial Response.

**Supplementary Figure 3. (A) Overall survival (OS) and (B) progression-free survival (PFS) in Cohorts 1 and 2**